

# Gemini Stock Analysis Report

---

Based on the detailed analysis of the attached 23-page report for **ZYDUSLIFE.NS** (Zydus Lifesciences Ltd.), here is my assessment.

**Important Note:** The report data is generated with a date of **2026-01-31**. I have performed this analysis treating the report's timeline as "current" relative to the price action shown.

## Step 1: Audit the Data

- **Data Present:**
    - **Price Structure:** Daily and Weekly candlestick charts with up-to-date pricing (INR 885.30).
    - **Trend Indicators:** EMA (20, 50, 200), Supertrend, and MACD analysis.
    - **Volatility:** Bollinger Bands and Squeeze analysis.
    - **Momentum/Strength:** RSI, Relative Strength (RS) against CNXPHARMA, and RS Composite scores.
    - **Volume:** Volume moving averages and Distribution/Accumulation day counts.
    - **Fundamentals:** Snapshot of revenue/EPS growth and valuation metrics.
  - **Data Missing:**
    - **Fibonacci Retracements:** No specific Fibonacci levels provided to identify key support/retracement zones below current price.
    - **Order Flow/Market Depth:** No intraday data to gauge immediate liquidity at support.
  - **Confidence Level: High.** The report provides a comprehensive technical and fundamental view, allowing for a decisive conclusion regarding the trend.
- 

## Step 2: Analyze the Setup

The current setup for ZYDUSLIFE.NS is **Bearish** and currently invalid for a long positional trade.

- **Price Structure & Trend:** The stock is in a "Strong **Downtrend**." It has been making lower highs and lower lows since peaking above INR 1300. The current price (INR 885.30) is trading below all key Exponential Moving Averages (20, 50, and 200). The 200 EMA at INR 942.94 acts as a formidable overhead resistance ceiling.
  - **Momentum:**
    - **RSI:** At 42.95, RSI is in bearish territory. It is not oversold enough to trigger a mean-reversion bounce, nor strong enough to suggest a trend change.
    - **MACD:** The histogram is slightly positive (1.68), suggesting selling pressure has paused temporarily, but the MACD line remains deep in negative territory (-8.44).
    - **Supertrend:** The signal is explicitly "SELL" (value 920.17).
  - **Volume Analysis:** The report identifies "Distribution Days" as recently as Jan 20th and Jan 30th, 2026. This indicates institutional selling into the current weakness.
  - **Relative Strength:** The stock is underperforming its sector (Pharma) and the broader market. The RS score is mediocre (47.6/100).
  - **Confluence:** There is **negative confluence**. Daily, Weekly, and 15-minute timeframes all align with a "Sell" or "**Downtrend**" status.
- 

## Step 3: Formulate the Recommendation

**Recommendation:** **NO** (Do not enter now).

**Reasoning:** Entering now would be "catching a falling knife." The stock is trapped below significant resistance layers. For a 1-4 month positional trade with a 5-15% upside probability, the stock must prove it

# Gemini Stock Analysis Report

---

has finished correcting by reclaiming key moving averages. The upside is capped by the 200 EMA (INR 943) and Supertrend (INR 920), offering poor risk-to-reward ratios at the current price.

**Conditional Plan (Watchlist for Reversal):** We require a structural break in market structure to justify a long entry.

- **Condition to Buy:** The stock must close decisively above the **200 EMA** and the **Supertrend Resistance**. This would confirm the end of the intermediate downtrend.
- **Entry Price: INR 946.00** (Wait for a daily close above INR 945 to clear the 200 EMA).
- **Stop Loss: INR 910.00** (Approximately 3.8% risk. Placed just below the 50 EMA, which should act as dynamic support post-breakout).
- **Take Profit: INR 1,050.00** (Approximately 11% upside. This targets the psychological round number and previous swing high consolidation zones).

## News & Analyst Targets

Current time: **Saturday, January 31, 2026**

Here is the latest stock research and analysis for **Zydus Lifesciences (ZYDUSLIFE)** for the week ending January 31, 2026.

### 1) Latest News for ZYDUSLIFE (Week of Jan 26-31, 2026)

- **Q3 FY26 Results Board Meeting:** The company announced that its Board of Directors will meet on **February 9, 2026**, to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2025.
- **USFDA Inspection Closure (Ankleshwar Unit-2):** The USFDA inspection conducted at the Ankleshwar Unit-2 facility from **January 19-23, 2026**, has concluded. The inspection closed with **3 observations**, but crucially, there were **no data integrity related observations**. The company stated it will address these observations expeditiously.
- **Launch of "Tishtha" (Nivolumab Biosimilar):** Zydus launched **Tishtha**, the world's first biosimilar of the cancer drug Nivolumab, in India. This is a significant milestone in making advanced oncology treatments more affordable.
- **USFDA Approvals:**
  - Received final approval for **Verapamil Hydrochloride Extended-Release Tablets** (generic of Calan SR) in strengths of 120 mg, 180 mg, and 240 mg.
  - Received a **Closeout Letter** from the USFDA regarding a Warning Letter issued in August 2024, officially marking the resolution of those regulatory issues.
- **Expansion (Group Level):** Zydus Hospitals (associated group entity) acquired **VINS Hospital** in late January to expand its neurology and neurosurgery capabilities, signaling continued growth in the broader healthcare footprint.

### 2) Brokerage Upgrades & Downgrades

- **Upgrade to BUY (Systematix):** On **January 20, 2026**, brokerage firm **Systematix Institutional Equities** upgraded Zydus Lifesciences to a **BUY** rating (from Hold/Neutral). They cited the improved earnings visibility from the US specialty business and the recent approval of **Zycubo** (for Menkes disease) as key drivers for the upgrade.
- **General Consensus:** Most domestic brokerages remain positive to neutral, citing the company's strong US pipeline and specialty launches as offsets to base business price erosion.

### 3) Indirect & Sector News Impacting ZYDUSLIFE

# Gemini Stock Analysis Report

- **Pharma Sector Q3 Previews:** Industry analysts expect the Indian pharma sector to deliver steady Q3 FY26 performance. Zydus is projected to report margin expansion driven by a favorable product mix (more complex generics and biosimilars) and cost efficiencies, despite broader pricing pressure in the US generics market.
- **Regulatory Tailwinds:** The receipt of the USFDA closeout letter removes a significant regulatory overhang, potentially improving investor sentiment toward the company's compliance standards.

## 4) Analyst Targets (January 2026)

The following table summarizes the latest price targets and ratings released by analysts in January 2026.

Brokerage / Firm	Rating	Target Price (INR)	Date of Report	Key Rationale
Systematix	BUY (Upgrade)	1,038	Jan 20, 2026	Added contributions from Zycubo and Lucentis biosimilar; raised target multiple. Growth visibility supported by specialty-led launches and disciplined execution. Aggregated average from multiple analysts; represents ~17% upside from current levels. Valuation based on FY26E EPS estimates; noted earnings above expectations.
DRChoksey	BUY	1,121	Jan 07, 2026	
Trendlyne Consensus	Hold/Accumulate	~1,040	Jan 28, 2026	
Choice Broking	Add	936	Jan 2026*	

*\*Note: Choice Broking target derived from recent FY26 estimation notes.*

**Summary:** The stock is currently trading around the **885-895 INR** level. Analyst sentiment has skewed slightly more positive this month due to the resolution of USFDA regulatory issues and the successful launch of new biosimilars.


# Stock Detailed Analysis Report

**ZYDUSLIFE.NS**

Current Price: ₹885.30

Generated: 2026-01-31 11:35

# ZYDUSLIFE.NS - 3 Year Daily Price Chart



## Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	Yes	18.68%	15.04%
Net Income	Yes	Yes	17.26%	0.28%
ROE	No	Yes	-2.93%	-10.55%
EPS	Yes	Yes	17.91%	0.86%

## Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	2.81%	2.59%
Net Income	Yes	25.27%	4.04%
ROE	Yes	17.08%	17.08%
EPS	No	12.25%	-11.77%

# ZYDUSLIFE.NS - Relative Strength Analysis

## == OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	<b>Emerging Leader</b>
RS Score:	47.6/100

:

## == RS RATIOS ==:

1M RS:	<b>1.007 [Leader]</b>
3M RS:	<b>0.920 [Neutral]</b>
6M RS:	<b>0.929 [Neutral]</b>
1Y RS:	<b>0.942 [Neutral]</b>

:

## == TURNAROUND ANALYSIS ==:

Turnaround Status:	<b>Not Detected</b>
--------------------	---------------------


:

## SIGNAL CRITERIA::


✓ Emerging RS:	1M (1.007) > 3M (0.920)
✓ Medium-term Lagging:	6M=0.929, 1Y=0.942 ( $\leq 1.0$ )
✗ Performance Improving:	<b>Not improving</b>

Relative Strength Analysis: ZYDUSLIFE.NS vs ^CNXPHARMA  
Classification: Emerging Leader


Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)



RS Composite Score Timeline






## ZYDUSLIFE.NS - EMA Crossover Summary

EMA 20:	893.73
EMA 50:	912.78
EMA 200:	942.94
Trend Status:	<b>Strong Downtrend</b>


ZYDUSLIFE.NS EMA Crossover Analysis



## ZYDUSLIFE.NS - Bollinger Bands Summary

<b>Current Price:</b>	885.30
<b>Upper Band:</b>	930.68
<b>Middle Band (SMA 20):</b>	894.78
<b>Lower Band:</b>	858.87
<b>%B:</b>	0.3680
<b>Band Width:</b>	0.0803
<b>Status:</b>	Lower Half
<b>Signal:</b>	None
<b>Recent Signal 1:</b>	<b>Buy Signal at 2025-11-07 00:00:00+05:30</b>
<b>Recent Signal 2:</b>	<b>Buy Signal at 2025-12-18 00:00:00+05:30</b>
<b>Recent Signal 3:</b>	<b>Buy Signal at 2026-01-13 00:00:00+05:30</b>


ZYDUSLIFE.NS Bollinger Bands (20, 2) Analysis



## ZYDUSLIFE.NS - Supertrend Summary

Status:	<b>DOWNTREND (Sell)</b>
Supertrend Value:	920.17
Signal Identified On:	2025-09-26

Supertrend Analysis for ZYDUSLIFE.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




## ZYDUSLIFE.NS - MACD Summary

MACD Line:	-8.44
Signal Line:	-10.12
Histogram:	1.68
Trend:	<b>Bullish</b>
Momentum:	<b>Weakening</b>
Signal:	None

ZYDUSLIFE.NS Price



ZYDUSLIFE.NS MACD (12, 26, 9)








# ZYDUSLIFE.NS - Volatility Squeeze Summary

BB Width:	0.0803
ATR:	16.3500
Total Signals:	31
Signal 1:	BB Squeeze + ATR Contraction at 2026-01-02 00:00:00+05:30 (Pr
Signal 2:	BB Squeeze + ATR Contraction at 2026-01-05 00:00:00+05:30 (Pr
Signal 3:	BB Squeeze + ATR Contraction at 2026-01-06 00:00:00+05:30 (Pr
Signal 4:	BB Squeeze + ATR Contraction at 2026-01-07 00:00:00+05:30 (Pr
Signal 5:	BB Squeeze at 2026-01-08 00:00:00+05:30 (Price: 907.55)


# ZYDUSLIFE.NS - Volatility Squeeze Analysis




## ZYDUSLIFE.NS - RSI-Volume Summary

<b>Current RSI:</b>	42.95
<b>Current Volume:</b>	662044
<b>Volume MA 20:</b>	540377
<b>Bullish Divergences:</b>	5
<b>Bearish Divergences:</b>	3
<b>Bullish Div 1:</b>	Date: 2025-03-03 00:00:00+05:30, Price: 860.59
<b>Bullish Div 2:</b>	Date: 2025-11-21 00:00:00+05:30, Price: 924.30
<b>Bearish Div 1:</b>	Date: 2025-07-01 00:00:00+05:30, Price: 991.15
<b>Bearish Div 2:</b>	Date: 2025-09-18 00:00:00+05:30, Price: 1047.85


# ZYDUSLIFE.NS RSI-Volume Divergence Analysis



## Relative Strength Index (RSI)



## Volume with Moving Averages



# ZYDUSLIFE.NS - Volume Analysis

## == VOLUME ANALYSIS ==:

Status:

**30 Signals Detected**

:

**2025-12-30 [-]:**

Distribution Day

**2026-01-07 [-]:**

Distribution Day

**2026-01-09 [-]:**

Distribution Day



**2026-01-20 [-]:**

Distribution Day

**2026-01-30 [-]:**

Distribution Day

# ZYDUSLIFE.NS - Volume Analysis




## Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	DOWNTREND (Sell)	941.44	885.3	2025-11-03
1 Day	DOWNTREND (Sell)	920.17	885.3	2025-09-26
15 Min	DOWNTREND (Sell)	892.41	888.85	2026-01-30

## Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bearish	Weakening	No Signal
1 Day	Bullish	Weakening	No Signal
15 Min	Bullish	Strengthening	No Signal

ZYDUSLIFE.NS - 1 Week (Candlestick + EMAs)



ZYDUSLIFE.NS - 1 Day (Candlestick + EMAs)




ZYDUSLIFE.NS - 15 Min (Candlestick + EMAs)






Trendlyne Snapshot - ZYDUSLIFE\_main



## Trendlyne Snapshot - ZYDUSLIFE\_forecaster



### Zydu Lifesciences - ZYDUSLIFE - stock price prediction, stock forecast, target price, analyst ratings from 30 analysts

Zydu Lifesciences has a share price target of Rs 1014, revenue growth forecast of 10.6%, and profit growth estimate of 2.9% for FY26, based on top 30 analyst calls.



#### Upgrade Your Plan

You need to upgrade your subscription plan to access this feature

Upgrade Now

Sign in

#### SAMPLE DATA BELOW

